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Abstract
Long considered immunologically “bland,” apoptotic cells are now recognized as important modulators of immune
responses. The role of apoptosis in immunological homeostasis has been inferred from several ﬁndings, for example,
induction of tolerance after injection of apoptotic cells and the capacity of APCs like macrophages and DCs to induce and
maintain tolerance after phagocytosis of dead cells. Processing of apoptotic cells by DCs is of particular interest, because
DCs are the only known APCs capable of activating naı ¨ve T lymphocytes to become effector or regulatory cells. In that
regard, recent evidence suggests that phagocytosis of apoptotic cells by DCs can induce Tregs, a ﬁnding that has
signiﬁcant implications for the treatment of a variety of immune-mediated inﬂammatory disorders. Here, we review the
relationship between apoptotic cells, DCs, and Tregs, and its impact on prevention of transplant rejection and treatment
of autoimmune diseases.
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Introduction
Fifty to seventy billion cells die daily of apoptosis in
the average human adult (Reed 1999), and for many
years it was believed that these cells had little effect on
the immune system. However, apoptotic cells are now
thought to provide a source of antigens to establish
peripheral tolerance, and can also induce strong
immunogenic responses after infection by a pathogen.
The remarkable capacity of apoptotic cells to induce
either tolerogenic or immunogenic responses makes
them attractive candidates to intervene in many
diseases. Since the immune responses triggered by
apoptotic cells are generally the result of their
processing by APCs, it is reasonable to propose that
the immunological mechanisms underlying treat-
ments based on induction of apoptosis will closely
mimic those operating in physiological immune
responses. Thus, apoptotic cells could provide a
means of treating diseases that is both safe and potent.
Apoptosis plays an important role in inducing and
maintaining immune unresponsiveness to self-anti-
gens via both central and peripheral tolerance. Most
autoreactive T lymphocytes with high avidity for
MHC-self peptide complexes are eliminated in the
thymus through apoptosis (Sprent and Kishimoto
2001). However, some do exit the thymus to the
ISSN 1740-2522 print/ISSN 1740-2530 online q 2006 Taylor & Francis
DOI: 10.1080/17402520600834704
Correspondence: A. Escher, Loma Linda University, 11234 Anderson Street, Room 2576, Loma Linda, CA 92354, USA.
Tel: 1 909 558 1000. Ext. 81423. Fax: 1 909 558 0486. E-mail: aescher@llu.edu
Clinical & Developmental Immunology, June–December 2006; 13(2–4): 273–282periphery, where deletion, anergy, and Tregs check
their activities. It is clear that a certain level of control
is mediated by APCs, which include DCs that have
processed apoptotic cells generated under steady-state
conditions (Chernysheva et al. 2002; Chung et al.
2006). After phagocytosis, the DCs migrate to local
draining lymph nodes where they present self-antigens
to T lymphocytes to induce and maintain tolerance
(reviewed by Skoberne et al. 2005). Similar events
have been observed when using apoptosis for
induction of peripheral tolerance to treat pathogenic,
immune-mediated inﬂammations. In this article, we
review and discuss recent concepts relating to
immunoregulatory apoptosis, and its role in the
induction of peripheral tolerance for intervention in
transplantation and autoimmune diseases.
Apoptosis and DCs
Under steady-state conditions, internalization by
peripheral DCs of self-antigens carried by apoptotic
cells induces tolerance that protects cells and tissues
fromthedamagesofpathogenicautoimmunityaswellas
immune responses induced by viral and bacterial
infections(Skoberneetal.2005).Thesamemechanism
may be invoked to explain antigen-speciﬁc tolerance
inducedbyapoptoticcellsthatcontainautoimmuneand
donorantigensinmodelsofpathologicalautoimmunity
and transplantation. A wide variety of parameters are
likely to be involved in determining whether a DC
becomes tolerogenic or immunogenic after uptake of
apoptoticcells.Forexample,itisknownthatearlystage
compared to late stage apoptotic cells are more likely to
induce tolerance (Sauter et al. 2000; Chernysheva et al.
2002; Ip and Lau 2004), and that molecules
displayed on the surface of apoptotic cells (Skoberne
et al. 2006), number of apoptotic cells (Ronchetti
et al. 1999), receptor and cytokine milieu (Chen et al.
2001a,b; Albert 2004), presence or absence of danger
signals (Feng et al. 2003), and interaction with other
cells (Skoberne et al. 2005) can all contribute to
determine different types of immune response.
In addition, the state of DC maturity can play a role
in the induction of tolerogenicity or immunogenicity.
Immunogenic responses are generally associated
with mature DCs, which display high numbers of
MHC-II and co-stimulatory molecules. However, it is
more difﬁcult to establish a correlation between the
maturity state of a DC and its tolerance-inducing
function. Early evidence indicated that tolerance
in the periphery is controlled by immature DCs
(Steinman et al. 2000). However, it is becoming clear
that semi-mature and mature DCs can also induce
antigen-speciﬁc tolerance (Chernysheva et al. 2002;
Lutz and Schuler 2002; Verhasselt et al. 2004).
Moreover,tolerogenicDCdonotappeartoberestricted
toaspeciﬁccelllineage,becausebothplasmacytoidand
myeloid DCs have been reported to be tolerogenic
(Fugier-Vivier et al. 2005; MacDonald et al. 2005;
Steptoe et al. 2005). This remarkable plasticity of
DCs is likely a reﬂection of the crucial importance
of maintaining immune tolerance and controlling
damages inﬂicted by immunogenic responses under a
variety of circumstances.
Dendritic cells can induce tolerance through several
mechanisms after engulﬁng antigen-loaded apoptotic
cells. Steinman and colleagues found that capture by
DCs of dying syngeneic TAP
2/2 splenocytes loaded
withsmallamountofovalbumin(OVA)resultsinOVA-
speciﬁc deletional tolerance in situ (Bonifaz et al.
2002). A single injection of small amounts of OVA
(,150ng/mouse) deletes more than a million antigen
speciﬁc CD8
þ T cells. After uptake of OVA-loaded
dying cell by CD8
þ splenic DCs, OVA-speciﬁc CD8
þ
T lymphocytes from transgenic mice are driven into
cell cycle, deleted, and the animals become tolerant to
OVA rechallenge. Moreover, when DCs are matured
after exposure to anti-CD40 antibodies, the same
approach causes immunity towards OVA with
increased production of IL-2 and IFN-g. Similarly,
Kusuhara and co-workers have reported that OVA-
pulsed, CD95 ligand-transduced killer DCs cause
rapid apoptosis of OVA speciﬁc naı ¨ve CD4
þ T cells
in vitro and in vivo (Kusuhara et al. 2002), while Min
etal.(2001)havereportedthatFASligand-transfected
DCs induce apoptosis of antigen-speciﬁc CD8
þ T
cells. Other data also indicate that immature DCs can
deliverapoptoticsignalstoantigen-speciﬁcTcells,and
cause them to undergo abortive proliferation and
deletion(Iyodaetal.2002;Claytonetal.2003;Morelli
et al. 2003; Fugier-Vivier et al. 2005). Figure 1 depicts
the possible interactions between DCs and Tregs and
the different events involving apoptotic cells.
Remarkably, apoptotic DCs by themselves appear
to play a signiﬁcant role in induction of tolerance.
Chen et al. (2006) have shown in a transgenic mouse
model that expression of the baculovirus caspase
inhibitor p35 by DCs results in their accumulation,
chronic lymphocyte activation, and autoimmunity
indicated by increasing antinuclear antibodies (ANA)
in mice older than 9 months. In contrast, transgenic
mice expressing p35 in their T or B cells do not
generate ANA, indicating a deﬁnite role of apoptotic
DCs in maintenance of tolerance. In another study, it
was shown that apoptotic DCs are responsible for
antigen-speciﬁc tolerance induced after injection of
apoptotic splenocytes (Maeda et al. 2005). A potential
explanation for these results is that apoptotic DCs can
no longer upregulate co-stimulatory molecules to an
immunogenic level, but still retain their tolerogenic
APC function.
Apoptosis and Tregs
Little is known regarding a possible link between
phagocytosis of apoptotic cells and induction of Tregs.
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knowledge of the bidirectional relationship between
DCs and Tregs, including the effects of tolerogenic
DCs that process apoptotic cells on Tregs. For
example, DC-expanded, antigen-speciﬁc Tregs show
greatly enhanced efﬁcacy relative to polyclonal
populations in blocking experimental autoimmunity,
indicating a functional relationship between DCs and
Tregs (Tarbell et al. 2006).
Considering the importance of active suppression
in maintaining tolerance, it is reasonable to propose
that the constant homeostatic ﬂux of apoptotic cells
generated in vivo could result in induction of Tregs
(Ferguson et al. 2002; Barratt-Boyes and Thomson
2005; Morelli 2006).
Evidence suggesting a possible role for Tregs in
apoptosis-inducedtolerancewasobtainedfromstudies
of Treg-associated cytokine secretions, which have
been reviewed elsewhere (Aubin and Mousson 2004).
For example, loading immature DCs with apoptotic
splenocytes induces cardiac allograft tolerance
accompanied by secretion of anti-inﬂammatory IL-10
(Xu et al. 2004). Further, over-expression of IL-10 in
the cardiac allograft after gene transfer augments Fas-
andBax-mediatedapoptosisofgraft-inﬁltratingCD4
þ
and CD8
þ T lymphocytes (Tung et al. 2003).
In addition, other investigators have shown that
intravenous infusion of apoptotic splenocytes either
donor, third party, or even of recipient origin, together
with allogeneic BM graft can induce humoral immune
tolerance in sublethal-irradiated recipient mice
(Perruche et al. 2004). The induced humoral
tolerance shows as a near absence of antibodies-
mediated allo-cytotoxicity, together with an immune
deviation shifted from type 1 to 2 response, which
exhibited as anti-donor cytotoxic antibodies (IgG2a)
decreased to normal level compared to non-apoptotic
infusion BM recipient controls. Such an apoptotic cell
induced humoral tolerance is TGFb dependent,
suggesting a possible role for Tregs, but has no effect
on the BM graft alone control even with a higher BM
cell number.
More direct evidence for induction of Tregs after
apoptotic cell infusion comes from a study of self-
leukocyte extracorporeal photopheresis using PUVA
(UVA plus psoralen, such as 8-methoxypsoralen, a
DNA-intercalating agent acting as photosensitizer).
In that study, PBMC from four individually organ-
transplanted infants were exposed to PUVA in vitro
and re-injected at regular intervals. Photopheresis was
shown to cause equally apoptosis of T, B, and NK
cells, as well as monocytes in the PBMC. Using an
in vitro test, DCs isolated following PUVA treatment
were shown to remain immature and to phagocytose
apoptotic cells. Using an in vivo test, Tregs were
shown to be the only cell population with signiﬁcant
Figure 1. Dendritic cells as inducers for antigen speciﬁc tolerance. Phagocytosis of antigen-carrying apoptotic cell by peripheral DCs can
induce antigen-speciﬁc tolerance. Whether the outcome is tolerance or immunity likely depends on many factors, such as the physiological
conditions, type of phagocyte, nature of receptors and cytokines, site of phagocytosis, and interaction with other cells, for example, regulatory
T cells. Although immature DCs are the most effective cells in this process, semi-mature and even mature DCs can be tolerogenic under
certain conditions. Moreover, bothplasmacytoid and myeloid DCs can be tolerogenic. Such DCs mayalsodeliverapoptotic signals,instead of
activation signals, to antigen-speciﬁc T cell clones and induce abortive proliferation as well as subsequent deletion.
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Most importantly, the PUVA-induced increase in
Treg activity lasted up to 1 year after the last exposure
in 50% of the patients (Lamioni et al. 2005). Other
investigators have also shown that intravenous infu-
sion of apoptotic splenocytes into mice directly
induces suppressive Tregs that are TGF-b-dependent,
Foxp3
þ,CD62L
high, and CTLA-4
þ(Kleinclauss et al.
2006). However, in that model system, BM graft
tolerance induction is mediated by host macrophages,
but not by host DCs or donor phagocytes.
Additional information on Treg induction by
apoptotic cells comes from mouse models of hapten
and contact hypersensitivity (reviewed by Barratt-
Boyes and Thomson (2005) and Morelli (2006)).
Infusion of PUVA-treated and pooled splenocytes and
lymph node cells into syngeneic naı ¨ve mice causes
inhibition of hapten immune response (Maeda et al.
2005). Inhibition depends on CD11c
þ DCs in the
donor cell population and induces antigen-speciﬁc
CD4
þCD25
þ Tregs in the recipient. Deleting the
CD11c
þ population, but not T cells, in the PUVA
treated donor cells, causes loss of tolerance in the
recipients. Hapten tolerance can be maintained in
recipient mice after adoptive transfer, but only when
the transferred leukocyte pool contains CD4
þCD25
þ
Tregs which release IL-10 and TGF-b. These results
underscore the notion that DCs and Tregs, respect-
ively, induce and maintain tolerance after exposure to
apoptotic cells.
In animal models of autoimmune diseases, Tregs
play a major role in maintaining antigen-speciﬁc
tolerance to self, although evidence suggests that
Tregs likely act at a later phase in the genesis of disease
(Marleau and Sarvetnick 2005). As in the case of
transplantation, data indicate that induced apoptosis
has the potential to activate antigen-speciﬁc Tregs and
ameliorate pathological autoimmunity. Indeed, work
done in our laboratory shows that a pro-apoptotic
DNA vaccine encoding BAX and a secreted form of
the b cell antigen GAD recruits DCs and induces
foxp3
þ Tregs in the NOD mouse model for type 1
diabetes (Li et al. 2004, 2006). Dendritic cells isolated
from treated mice can suppress T cell proliferation
after pulsing with GAD polypeptide (unpublished
results), and Tregs cultured from pancreatic draining
lymph node under GAD pulse show suppressive
function and express the foxp3 gene (Li et al. 2006).
These data suggest that induction of apoptosis in vivo
can result in antigen-speciﬁc tolerance, most likely
mediated by DCs and Tregs. Additional data indicate
that antigen-speciﬁc foxp3
þ Tregs induced by GAD-
containing apoptotic cells may have developed from
CD4
þCD25
2 foxp3
2 T cell populations (Li et al.
2006). However, the relationship between apoptotic
cell-induced DCs and antigen-speciﬁc Tregs remains
to be established in vivo in this model system.
Interestingly, reports from other laboratories indicate
that AICD of effector T cells is required for the
induction of suppressive Tregs in autoimmune
tolerance models, but the relationship between DCs,
Tregs, and AICD remains obscure. CD4
þCD25
þ
Tregs are particularly sensitive to AICD, which results
in increased or decreased CD4
þCD25
þ Tregs activity
and cell number (Chen and Brosnan 2006). Activated
CD4
þCD25
þ Tregs themselves can control auto-
immunity by inducing AICD (Madakamutil et al.
2003). For example, immunization with myco-
bacterial preparation Bacille Calmette-Guerin
(BCG) prevents the onset of diabetes in NOD mice
by inducing TNF-a/IFN-g-induced apoptosis of
diabetogenic T cells through both Fas and TNF
pathways (Qin et al. 2004). In otherexamples, aMHC
II-peptide octamer of HA antigen delays the onset of
diabetes in TCR-CD4/RIP-HA double transgenic
mice via clonal deletion of diabetogenic CD4 T cells in
both thymus and peripheral lymphoid organs through
AICD, while the MHC II-peptide dimmer of HA
protects against diabetes by induction of IL-10
secreting Tr-1 cells in the pancreas (Preda-Pais et al.
2005), and treatment of DCs with 1a, 25-Dihydrox-
yvitamin D3 or its analogue plus autoantigen (GAD or
insulin) selectively induces apoptosis of human
autoreactive T cell clones (van Halteren et al. 2004).
Altogether, these data suggest a relationship between
Tregs and apoptotic cells that can lead to tolerance
(Figure 2).
In another animal model of pathogenic auto-
immunity, Madakamutil and co-workers have
reported that expansion of CD4
þ and CD8
þ Tregs
results in apoptotic deletion of Vb8.2
þT cells reactive
to the autoantigen myelin, and protection from EAE
in vivo (Madakamutil et al. 2003). In addition,
Ferguson et al. (2002) have shown that by using i.v.
injection of apoptotic trinitrophenyl (TNP)-coupled
splenocytes as tolerogen, uptake of the apoptotic
tolerogen-coupled cells by CD8
þCD11c
þ DCs cross-
present antigen in a MHC I-dependent manner to
regulatory CD8
þT cells, and induces immune
unresponsiveness. A subsequent study showed that
i.v. injection of soluble peptide antigen-OVA emulsi-
ﬁed 1:1 in CFA caused deletion of a large number of
antigen speciﬁc DO11.10-transgenic T cells by CD8
þ
cytotoxic T cells via predominately Fas/FasL apopto-
tic mechanism, resulting in antigen-speciﬁc tolerance
in vivo (Herndon et al. 2005). Altogether, these results
suggest that there may be an additional level of control
at play when relatively large numbers of peripheral T
cells become apoptotic, i.e. active immunoregulation
can be directed toward antigen-reactive cells to
control self-responses when large numbers of T cells
die and release potentially dangerous autoantigens
and cytokines.
This body of evidence indicates that it is possible to
induce antigen-speciﬁc Tregs in vivo to delete
autoreactive cell clones and ameliorate disease in
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CD4
þCD25
þ Tregs may act as an initial suppression,
and then induce secondary suppression by activating
Tr1 or Th3 cells to extend tolerance to other
population of lymphocytes (Stassen et al. 2004).
However, a clear link between apoptosis-tolerized
DCs, antigen-speciﬁc Tregs, and deletion of auto-
reactive cells remains to be ﬁrmly established.
Apoptosis for intervention in transplantation:
Application to mixed chimerism
Combined infusion of HCs and solid organ trans-
plantation, which is performed together with non-
myeloablative regimens or less intensive conditions, is
one of the most promising research directions for
induction of antigen-speciﬁc transplant tolerance
(Ferrand et al. 2003). Full chimerism, where the
hematopoietic system of the recipient is replaced by
that of the donor following ablative conditioning, is
associated with high morbidity and mortality that limit
its application in the clinic. In contrast, mixed
chimerism refers to a state where allogeneic HCs
coexist with recipient cells, which can be induced in
adult animals by administering T cell-depleted
allogeneic and host marrow cells following high
doses of total lymphoid irradiation, or recently even
with non-myeloablative regimens (Sykes 2001) by
using DST. The term “macrochimerism” is used to
describe the persistence of high levels of donor cells in
recipients, as observed after allogeneic HCs trans-
plantation, and “microchimerism” is refer to the
persistence of a small number of donor cells that are
detectable using molecular techniques (Ferrand et al.
2003).
Mixed chimerism offers signiﬁcant advantages over
full chimerism: (1) it is less toxic; (2) it can establish
tolerance across complete MHC barriers, which is a
basic requirement for organ transplantation; and (3)
because of the coexistence of host- and donor-derived
hematopoietic APC in the thymus, intrathymic
deletion of host-reactive cells in addition to donor-
reactive cells occurs in mixed chimeras to a greater
extent than in full chimeras. The minimal, nontoxic
host conditioning regimens for mixed chimerism
induction offers a hopeful future for clinical trans-
plantation. In that regard, evidence indicates that
delivery of apoptotic cells is a promising means to help
establishing mixed chimerism.
Infusion of apoptotic HCs is thought to have the
potential to induce robust chimerism, reduce the
requirements for immunosuppressors, and allow
Figure 2. Regulatory T cells as maintainers of antigen-speciﬁc tolerance. While DCs play a major role in inducing antigen speciﬁc T cell
apoptosis in an early phase of transplant rejection or autoimmunity, Tregs are necessary for maintaining tolerance over the long term.
Activated by DCs, CD4
þ and CD8
þ Tregs monitor the periphery and keep speciﬁc antigen reactive Tor B lymphocytes under control via
inactivation through cell-to-cell contact, secretion of cytokines, and apoptosis to protect tissues and organs from immune rejection and
autoimmunity.
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with grafting, rather than before grafting (Kleinclauss
et al. 2003b), which improves the clinical applicability
remarkably. Indeed, and as previously mentioned,
Saas and colleagues have shown that an infusion of
apoptotic mononuclear cells from different sources
can enhance tolerance to an allogeneic graft
(Bittencourt et al. 2001). The investigators used
intravenous injection of apoptotic cells in combination
with allogeneic bone marrow cells to induce macro-
chimerism and increase the success rate of bone
marrow transplantation (Kleinclauss et al. 2003a;
Perruche et al. 2003).
With the emerging role of Tregs in strategies where
apoptotic or non-apoptotic HCs infusion is combined
with organ transplantation, a link between Tregs and
establishment of chimerism has been postulated.
When only low level of donor chimerism persists, for
example, when high doses of HCs are given with non-
myeloablative regimens in solid organ transplantation,
maintenance of unresponsiveness can be achieved
through additional mechanisms, such as suppression
mediated by Tregs, to clear or inhibit remaining
donor-reactive Tor B lymphocytes (Kurtz et al. 2004;
Saas et al. 2004; Sykes et al. 2005). However, recent
reports have shown that, although CD4
þCD25
þ
Tregs may not be necessarily involved in the induction
of chimerism, they do playa role in the maintenance of
stable mixed chimerism established through BM
transplant with costimulatory blockade (CTLA4Ig
and anti-CD154) plus rapamycin in a non-myeloa-
blative skin-grafted mouse model (Zheng et al. 2003;
Domenig et al. 2005).
Observations made in the clinic can also help us to
understand further the role of apoptosis in induction
of transplant tolerance. For example, a group of
patients receiving kidney–pancreas transplant with
no rejection, under an immunosuppressive regimen
consisting of anti-thymoglobulin antibodies for 7 days
and cyclosporine/mofetil mycophenolate as mainten-
ance therapy, have shown higher intragraft apoptosis
(annexin V) and lower anti-apoptotic molecules
(lymphocytes CD95L, iNOs, and Bcl-2) together
with higher CD8, CD4DR expression in graft and
higher CD3CD25 expression in PBL compared to
healthy controls (Fiorina et al. 2004). However, the
controls from the same organ transplanted with
rejections were not compared in this report. In
another study, a comparison between acute non-
rejected and rejected human orthotopic liver trans-
plantations showed that non-rejecting subjects had
higher donor cell chimerism detected by PCR on day
0, and higher apoptotic recipient PBMC with increase
expression of IFNg, IL-10, and CD40L on day 1
when compared to acutely-rejected patients (Jonsson
et al. 2004). In the case of the unexpected restoration
of cardiac function via stem cell transplantation after
myocardial infarctions, it has been proposed that
apoptosis of transplanted stem cells modulate local
immune reactivities by down-regulating innate and
adaptive immunity (Thum et al. 2005). This may have
occurred through deactivation of macrophages and
DCs, as well as stimulation of Tregs, which could have
led to the observed reduced scar formation, repressed
myocardial apoptosis, and improved cardiac outcome.
These data indicate that induced or infused apoptotic
cells have signiﬁcant potential for future clinical
applications.
A drawback associated with using infused apoptotic
cells is the limited supply of donor BM or HC cells
that could be used as apoptotic cells in the clinic.
Therefore, it will be important to identify alternative
sources of apoptotic cells. For example, iliac crest,
progenitor from PBMC, cultured CD34
þ stem cells,
and NK1.1
þ TCRab
þ BM cells all have potential as
replacements for induction of chimerism using
tolerogenic apoptosis (Delis et al. 2006).
Apoptotic cells for intervention in autoimmune
diseases
Dysregulated apoptosis, whether interrupted or
accelerated, is thought to be a central defect in many
human and murine autoimmune diseases. Defective
apoptosis can contribute to different etiological
aspects of autoimmune disease, such as interruption
of central or peripheral T cell death that can lead to
AICD failure and increased numbers of autoreactive
cells, and disruption of organ-speciﬁc cell apoptosis
thatleadstoautoimmunereactivities(Kuhtreiberetal.
2003; Todaro et al. 2004). In the NOD mouse model
for type 1 diabetes, it was shown that down regulation
of LMP2/TAP1 molecules may be responsible for
impaired assembly of self peptide antigen-loaded
MHC I molecules, lead to faulty activation of pro-
inﬂammatory transcription factors such as NF-kB,
and result in impaired self-education of DCs and T
lymphocytes as well as increased sensitivities of
lymphocytes to TNF-a induced apoptosis (Kuhtrei-
ber et al. 2003). In addition, a NOD-speciﬁc, TCR-
induced, AICD-resistance proﬁle has been reported in
CD4
þ and CD8
þ T cells. Upon activation by anti-
CD3 antibodies, the NOD-derived T cells are more
resistant to AICD compared to C57BL/6, BALB/c,
and NOR T cells, accompanied with lower expression
of Fas and FasL, caspase 3 and 8 levels, IL-2 and IL-4,
and higher TGF-b and Bclx-L levels (Arreaza et al.
2003; Decallonne et al. 2003). Furthermore, Fas
functional defect is also observed in human T1DM
patients (Dianzani et al. 2003). The apoptotic defects
in different cell types and the consequent defective
T cell AICD could be responsible for defective
peripheral tolerance and development of T1DM.
Different laboratories have shown that induction of
apoptosiscanpreventor treatT1DMinanimalmodels.
Induction of TNF-a expression after administration of
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cells with self-antigen can interrupt autoimmune
diabetes in NOD mice through the loss of cells with an
increased sensitivity to TNF-a—induced apoptosis,
leading to long-term tolerance (Ryu et al. 2001).
Similarly, a transgenic mouse model expressing islet-
speciﬁc TNF-a abrogates T1DM through increasing
apoptosis of autoreactive CD8
þ lymphocytes at a time
when the disease is already ongoing (Christen and
Von Herrath 2002). In addition, nicotinamide, a poly
(ADP-ribose) polymerase inhibitor, is thought to
prevent spontaneous and recurrent diabetes in NOD
mice by inducing apoptosis of islet-inﬁltrating leuko-
cytes (Suarez-Pinzon et al. 2003).
Among the different pro-apoptotic strategies for
prevention or treatment of type 1 diabetes, DNA
vaccination could represent the simplest and most
practical means to intervene. As mentioned pre-
viously, we have reported that a DNA vaccine
encoding both a secreted form of the b-cell antigen
GAD and pro-apoptotic BAX in order to generate
apoptotic cells containing GAD antigen can prevent
autoimmune diabetes when delivered intramuscularly
(Li et al. 2004), and ameliorate new-onset diabetes
when injected intradermally in NOD mice (Li et al.
2006). We have proposed that the vaccine triggers
formation of GAD-containing apoptotic bodies in vivo
that induce tolerogenic DCs and Tregs. BAX in this
model can be taken as an adjuvant to promote the
prophylactic and therapeutic effects of the vaccine,
similarly to the apoptotic effect of vaccine adjuvants
that has been reported as an important factor for
induction of the differentiation and maturation of
DCs and activation of T cells (Yang et al. 2004).
However, BAX can also be used as an adjuvant to
induce immunogenic response (Kinsey et al. 2004).
Indeed, our own data indicate that, in contrast with a
secreted GAD vaccine, a plasmid encoding higher
amounts of intracellular GAD protein does not
prevent diabetes and is pro-inﬂammatory (Li et al.
2004). A possible hypothesis that could explain these
different results is that the lower amounts of GAD
contained in apoptotic bodies do not induce over
expression of molecular chaperones and other stress
proteins that are thought to act as danger signals (Feng
et al. 2003; Masse et al. 2004). Low amounts of GAD
antigen could maintain “subimmunogenic”
conditions that are known to favor conversion of
naı ¨ve T cells into Tregs (Kretschmer et al. 2005), and
result in tolerance for the antigen contained in
apoptotic cells. In addition to using DNA vaccination
to induce apoptotic cells as a source of tolerogenic
antigen, a different pro-apoptotic DNA vaccination
strategy has used plasmid DNA encoding antigen
(i.e. beta-galactosidase) and FasL to induces antigen-
speciﬁc peripheral T cell tolerance through the
induction of FasL-mediated antigen speciﬁc AICD
(Georgantas et al. 2000).
In the central nervous system, T cell AICD-
resistance is also considered important in the etiology
of EAE and MS, and induced apoptosis of CNS-
inﬁltrating lymphocytes improves the disease (Pender
1999; Pender and Rist 2001; Chen and Brosnan
2006). Intrathecal delivery of IFN-g protects mice
from chronic progressive EAE associated with
increased apoptosis of CNS-inﬁltrating lymphocytes
(Furlan et al. 2001). In addition, 1, 25-dihydroxy-
vitamin D3 reverses EAE by stimulating apoptosis in
CNS inﬂammatory cells such as macrophages and
CD4
þT cells (Spach et al. 2004).
In murine or human autoimmune arthritis, defec-
tive apoptosis of synoviocytes, T, and B lymphocytes
has been reported to be associated with disease onset,
characterized by chronic inﬂammatory cell inﬁltration
and synovial hyperplasia (Mountz et al. 2001; Zhang
et al. 2001; Lopez-Hoyos et al. 2003; Peng 2006).
Several interventions using induction of Fas or non-
Fas apoptotic pathway in different cell types have been
shown to be beneﬁcial in RA models, which have been
reviewed previously (Peng 2006). Recently, direct
evidence has shown that repeated injection of FasL
encoded by an adenovirus increases the number of
apoptotic cells in arthritic synovium and dramatically
reduced the size and weight of the synovium. This
approach has been named “gene scalpel” in reference
to synovectomy but without surgical damaging
(Zhang et al. 2005). In addition, intra-articular
injection of TRAIL, which induces apoptosis in
proliferating cells, encoding adenovirus or TRAIL
protein induces extensive synovial lining apoptosis as
well as decreasing inﬂammation in rabbit arthritis
models (Yao et al. 2006).
There is also evidence that autoimmune thyroiditis,
such as HT and GD, are apoptosis-related diseases.
Comparative research of human HT and GD shows
that in HT thyroid, the regulation of Fas/FasL/Bcl-2
favors thyrocyte apoptosis via homophylic Fas–FasL
interactions and a gradual reduction in thyrocyte
numbers leading to hypothyroidism. In contrast, the
regulation of Fas/FasL/Bcl-2 in GD favors apoptosis
of inﬁltrating lymphocytes and thus favors thyrocyte
survival and hyperthyroidism (Salmaso et al. 2002).
Induced apoptosis targeting different cell types in HT
or GD could have therapeutic effects on both of the
two forms of thyroid autoimmunity.
Conclusion
We are starting to recognize the fundamental
importance of apoptotic cells for the maintenance of
immune homeostasis, and to use apoptosis in a
rational manner to ameliorate diseases. However, it is
clear that a variety of molecular and cellular
parameters can greatly impact the immune response
induced by apoptosis. Considering that dying cells can
induce either tolerogenic or immunogenic responses,
Apoptosis and tolerance induction 279it will be vital to identify and control the
conditions that determine these two different out-
comes if apoptosis is to be used as an intervention in a
clinical setting.
Direct delivery of apoptotic cells will require
induction of apoptosis in vitro using UV, chemical,
or even genetic means before infusion, with the beneﬁt
of knowing the number and quality of the cells to be
delivered. Induction of apoptosis directly in vivo
appears more practical, could permit tissue-speciﬁc
induction of apoptosis, and be achieved using similar
means. However, the quantity and quality of the
induced apoptotic cells will be more difﬁcult to
evaluate. According to different needs, protocols
could be designed to use one or both strategies to
achieve optimal results. Because of its potential safety
and potency, therapeutic or even prophylactic
induction of apoptosis could offer a wide range of
applications for maintenance of tolerance in the ﬁelds
of graft transplantation, pathological autoimmunity,
and other immune-mediated inﬂammatory disorders.
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